Variable progression of autosomal dominant polycystic kidney disease: Genetic and molecular counterparts;Progression variable de la polykystose rénale autosomique dominante: Aspects génétiques et moléculaires

Nephrologie et Therapeutique

Volumn 2, Issue SUPPL. 2, 2006, Pages

  Devuyst, Olivier ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Modifier genes; Polycystic kidney disease; Variable disease phenotype

Indexed keywords

CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; POLYCYSTIN 1; POLYCYSTIN 2; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALLELE; AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DISEASE COURSE; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEREDITY; HUMAN; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE EPITHELIUM; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; SIBLING; SOMATIC MUTATION; TWINS;

DISEASE PROGRESSION; FAMILY; FEMALE; HUMANS; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 31544458171     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. rd Edition, Oxford University Press, Oxford, 2005, pp. 2304-2324.
2. Peters DJM, Breuning MH. Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 2001;358:1439-44.
3. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002;13:2384-98.
4. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet 1999;353:103-7.
5. Rossetti S, Strmecki L, Gamble V, Burton S, Sneddon V, Peral B, et al. Mutation analysis of the entire PKD1 gene: genetic and diagnostic implications. Am J Hum Genet 2001;68:46-63.
6. Rossetti S, Burton S, Strmecki L, Pond GR, San Millan JL, Zerres K, et al. The Position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol 2002;13:1230-7.
7. Magistroni R, He N, Wang K, Andrew R, Johnson A, Gabow P, et al. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2003;14:1164-74.
8. Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease-a contiguous gene syndrome. Nat Genet 1994;8:328-32.
9. Pei Y, Paterson AD, Wang KR, He N, Hefferton D, Watnick T, et al. Bilineal disease and transheterozygotes in autosomal dominant polycystic kidney disease. Am J Hum Genet 2001;68:355-63.
10. Pei Y. A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 2001;7:151-6.
11. Martin GM, Ogburn CE, Colgin LM, Gown AM, Edland SD, Monnat RJ Jr. Somatic mutations are frequent and increase with age in human kidney epithelial cells. Hum Mol Genet 1996;5:215-21.
12. Hall JG. Twinning: mechanisms and genetic implications. Curr Opin Genet Dev 1996;6:343-7.
13. Persu A, Duyme M, Pirson Y, Lens XM, Messiaen T, Breuning MH, et al. Comparison between silings and monozyogotic twins supports a significant role for modifier genes in autosomal dominant polycystic kidney disease. Kidney Int 2004;66:2132-2136.
14. Woo DD, Nguyen DK, Khatibi N, Olsen P. Genetic identification of two major modifier loci of polycystic kidney disease progression in pcy mice. J Clin Invest 1997;100:1934-40.
15. Guay-Woodford LM. Murine models of polycystic kidney disease: molecular and therapeutic insights. Am J Physiol Renal Physiol 2003;285:F1034-F1049.
16. Sullivan LP, Wallace DP, Grantham JJ. Epithelial transport in polycystic kidney disease. Physiol Rev 1998;78:1165-91.
17. O'Sullivan DA, Torres VE, Gabow PA, Thibodeau SN, King BF, Bergstralh EJ. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998;32:976-83.
18. Persu A, Devuyst O, Lannoy N, Materne R, Brosnahan G, Gabow PA, et al. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000;11:2285-96.
19. Baboolal K, Ravine D, Daniels J, Williams N, Holmans P, Coles GA, Williams JD. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997;52:607-13.
20. Persu A, El-Khattabi O, Messiaen T, Pirson Y, Chauveau D, Devuyst O. Influence of ACE (I/D) G460W polymorphism of a-adducin in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003;18:2032-8.
21. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002;11:229-41.
22. Walker D, Consugar M, Slezak J, Rossetti S, Torres VE, Winearls CG, Harris PC. The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am J Kidney Dis 2003;41:90-4.
23. Devuyst O, Persu A, Stoenoiu MS, Lens XM, Chauveau D, Pirson Y. ENOS polymorphism and renal disease progression in autosomal dominant polycystic kidney disease. Am J Kid Dis 2003;41:1124-5.
24. Fain PR, McFann KK, Taylor MR, Tison M, Johnson AM, Reed B, Schrier RW. Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 2005;67:1256-67.
25. Paterson AD, Magistroni R, He N, Wang K, Johnson A, Fain PR, et al. Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2005;16:755-62.